Prevalence, Determinants, and Outcomes of Low Disease Activity and Remission Attainment in Patients With Systemic Lupus Erythematosus That Is Clinically Active
Arthritis Care & Research · 2026-03 · 78 (3) · 378-387
DOI: 10.1002/acr.25640 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Arthritis Care & Research, online erschienen am 29.12.2025. Verfasst von Yanjie Hao und 39 weiteren Autor:innen. Beteiligte Einrichtung: The University of Melbourne and St. Vincent's Hospital Melbourne, Melbourne, Victoria, Australia, and Peking University First Hospital, Beijing, Chin…. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: GlaxoSmithKline, Eli Lilly Australia, AstraZeneca.
Abstract (Originalsprache)
Objective
This study aimed to identify in patients with systemic lupus erythematosus (SLE) with clinically active disease the attainment of frequency and determinants of Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) and the frequency and determinants of flare and damage accrual after target attainment.
Methods
Patients in a multinational cohort with SLE who had clinical disease activity but were not in LLDAS or DORIS were observed prospectively.
Results
A total of 1,991 patients (93.2% female) were observed for a median (interquartile range) of 2.5 (0.7–4.5) years, with 70.9% and 55.6% achieving LLDAS and DORIS, respectively. Nephritis and low complements were associated with a longer time, and antimalarial and immunosuppressant use were associated with a shorter time to LLDAS attainment. After the first LLDAS and DORIS attainment, 47.0% and 47.5% of the patients experienced flare(s), respectively, and 9.5% and 7.9 % of patients accrued organ damage within 24 months, respectively. Longer cumulative time at target and antimalarial use was associated with a longer time to flare and damage accrual, whereas dose reduction in glucocorticoids and immunosuppressants was associated with a shorter time to flare. Reduction in immunosuppressants also correlated with a shorter time to damage accrual.
Conclusion
In patients with SLE with clinical disease activity, the proportion attaining LLDAS and DORIS under usual care conditions is suboptimal. Longer maintenance of these states is significantly associated with reduced risk of flare. Because flares and damage accrual still occur frequently following initial target attainment, further research is needed to inform strategies for maintaining these targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The University of Melbourne and St. Vincent's Hospital Melbourne, Melbourne, Victoria, Australia, and Peking University First Hospital, Beijing, China.
- St. Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
- Monash University, Melbourne, Victoria, Australia.
- Chiang Mai University Hospital, Chiang Mai, Thailand.
- Taichung Veterans General Hospital, Taichung, Taiwan.
- National University Hospital, University Medicine Cluster, Singapore.
ORCID-Profile: Yanjie Hao, Rangi Kandane-Rathnayake, Yi-Hsing Chen, Jiacai Cho, Laniyati Hamijoyo, Yasuhiro Katsumata, Zhuoli Zhang, Tsutomu Takeuchi, Sang-Cheol Bae, Fiona Goldblatt, Yoshiya Tanaka, Shirley Chan, Alberta Hoi, Shereen Oon, Mandana Nikpour
Förderung
- GlaxoSmithKline
- Eli Lilly Australia
- AstraZeneca
- Union Chimique Belge
- Janssen Research and Development
- Bristol-Myers Squibb
- EMD Serono
- UCB
Zitieren
APA
Hao, Y., Hansen, D., Kandane-Rathnayake, R., Louthrenoo, W., Chen, Y. H., Cho, J., Lateef, A., Hamijoyo, L., Luo, S. F., Wu, Y. J., Navarra, S., Zamora, L., Li, Z., Sockalingam, S., Katsumata, Y., Harigai, M., Zhang, Z., Chan, M., Kikuchi, J., …, & Asia‐Pacific Lupus Collaboration (2026). Prevalence, Determinants, and Outcomes of Low Disease Activity and Remission Attainment in Patients With Systemic Lupus Erythematosus That Is Clinically Active. Arthritis Care & Research, 78(3), 378-387. https://doi.org/10.1002/acr.25640
Vancouver
Hao Y, Hansen D, Kandane-Rathnayake R, Louthrenoo W, Chen YH, Cho J, et al. Prevalence, Determinants, and Outcomes of Low Disease Activity and Remission Attainment in Patients With Systemic Lupus Erythematosus That Is Clinically Active. Arthritis Care & Research. 2026;78(3):378-387. doi:10.1002/acr.25640
BibTeX
@article{Hao2026,
author = {Hao, Yanjie and Hansen, Dylan and Kandane-Rathnayake, Rangi and Louthrenoo, Worawit and Chen, Yi-Hsing and Cho, Jiacai and Lateef, Aisha and Hamijoyo, Laniyati and Luo, Shue Fen and Wu, Yeong-Jian Jan and Navarra, Sandra and Zamora, Leonid and Li, Zhanguo and Sockalingam, Sargunan and Katsumata, Yasuhiro and Harigai, Masayoshi and Zhang, Zhuoli and Chan, Madelynn and Kikuchi, Jun and Takeuchi, Tsutomu and Bae, Sang-Cheol and Goldblatt, Fiona and O'Neill, Sean and Ng, Kristine Pek Ling and Law, Annie and Basnayake, B M D B and Tugnet, Nicola and Kumar, Sunil and Tee, Cherica and Tee, Michael and Ohkubo, Naoaki and Tanaka, Yoshiya and Chan, Shirley and Lau, C S and Golder, Vera and Hoi, Alberta and Oon, Shereen and Morand, Eric and Nikpour, Mandana and Asia‐Pacific Lupus Collaboration, Asia‐Pacific Lupus Collaboration},
title = {Prevalence, Determinants, and Outcomes of Low Disease Activity and Remission Attainment in Patients With Systemic Lupus Erythematosus That Is Clinically Active},
journal = {Arthritis Care & Research},
year = {2026},
volume = {78},
number = {3},
pages = {378--387},
doi = {10.1002/acr.25640}
}
EUVIMED